<ion-content>
    <ion-card>
        <ion-card-header color="primary" text-center>
            Type I
        </ion-card-header>
        <ion-card-content>
            Ceftriaxone / Cefotaxime (For Non - ESBL suspect)
            <span class="cardCustom"> (or)</span>
            Ampicillin / Sulbactum
        </ion-card-content>
    </ion-card>
    <ion-card>
        <ion-card-header color="primary" text-center>
            Type II
        </ion-card-header>
        <ion-card-content>
            Piperacillin / Tazobactam +/- Amikacin
            <span class="cardCustom"> (or)</span>
            Cefoperazone / Sulbactam +/- Amikacin
        </ion-card-content>
    </ion-card>
    <ion-card>
        <ion-card-header color="primary" text-center>
            Type III
        </ion-card-header>
        <ion-card-content>
            Meropenem + Amikacin
            <span class="cardCustom">(or)</span>
            Imipenem + Amikacin
            <span class="cardCustom">(or)</span>
            Cefepime (last resort reserve group)
        </ion-card-content>
    </ion-card>
    <ion-card>
        <ion-card-header color="primary" text-center>
            Type IV
        </ion-card-header>
        <ion-card-content>
            Based on IDSA Guildelines and risk factors empirical antifungal Flucanazole can be added if candida infection is suspected in Febrile Neutropenic patients
        </ion-card-content>
    </ion-card>
    <ion-card>
        <ion-card-header color="danger">
            NOTE :
        </ion-card-header>
        <ion-card-content>
            1. Renal Function to be assessed if INJ.Amikacin is to be continued<br>
            2. Vancomycin or Linezolid if MRSA is suspected<br>
            3. Metronidazole can be added if anaerobic cover of antibiotics is not adequate<br>
        </ion-card-content>
    </ion-card>
</ion-content>